Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies.
Hoffmann
L A
LA
Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University, Munich, Germany.
Krumbholz
M
M
Faber
H
H
Kuempfel
T
T
Starck
M
M
Pöllmann
W
W
Meinl
E
E
Hohlfeld
R
R
D000328:Adult; D000906:Antibodies / Q000097:blood* / Q000187:drug effects; D015415:Biomarkers / Q000097:blood; D005260:Female; D019204:GTP-Binding Proteins / Q000235:genetics*; D006801:Humans; D016899:Interferon-beta / Q000009:adverse effects* / Q000276:immunology*; D008297:Male; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D064547:Myxovirus Resistance Proteins; D011237:Predictive Value of Tests; D013997:Time Factors; D015533:Transcriptional Activation / Q000187:drug effects / Q000276:immunology; D015854:Up-Regulation / Q000187:drug effects / Q000276:immunology
D000906:Antibodies; D015415:Biomarkers; C579071:MX1 protein, human; D064547:Myxovirus Resistance Proteins; D016899:Interferon-beta; D019204:GTP-Binding Proteins